Navigation Links
FDA Stem Cell Approval Breakthrough Laudable
Date:1/23/2009

SAN CLEMENTE, Calif., Jan. 23 /PRNewswire/ -- Today the FDA announced approval for the first clinical trials on humans using Embryonic Stem Cells but Adult Stem Cell scientist Christian Drapeau says the experts may not be telling the whole story; Adult Stem Cells have greater potential with less risk.

"While the FDA approval is an exciting step forward toward freeing science from the shackles of politics," said Drapeau. "The expert commentary we're seeing surrounding the FDA's action is misleading."

Christian Drapeau, an early advocate of ASC science, posits that ACS are showing the greatest potential for scientific and medical advances.

Drapeau says that ASC can be a safer alternative to Embryonic Stem Cells because of a lower risk of tumor formation while studies show ASC to have comparable potential or even more in repairing damaged tissues or organs. This contradicts experts on morning talk shows who cast doubt on the efficacy of ACS research.

"The use of ASC requires a different thinking, but they can be as effective as ESC, if not more. ASC do not grow easily in vitro and they are not easy to re-program. But there are ways of using ASC that can be just as effective as methods using ESC, without the risk of tumor formation."

"Adult Stem Cells are showing great promise," notes Drapeau. "This is a very very important area of research right now and people must realize that Embryonic Stem Cells are not the only Stem Cell phenomenon out there."

"The scientific community is rejoicing today as a new age of medicine is ushered in concurrent with the Obama administration but the possibilities of Adult Stem Cell science are so mind boggling in terms of healing physical damage and the elimination of disease that the scientific community must focus on what works best, with the least amount of risk and the greatest scope of application," said Drapeau.

Media Contact: Maggie Jessup 360.521.0437 or maggie@platformstrategy.com

Christian Drapeau: America's best known advocate for Adult Stem Cell research and the medical applications of Adult Stem Cells. His theory that Adult Stem Cells are nothing less than the body's natural healing system has profound implications for every area of modern medicine. He holds a Masters degree in neurophysiology from the Department of Neurology and Neurosurgery at Montreal's McGill University. http://www.christiandrapeau.com


'/>"/>
SOURCE Christian Drapeau
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
3. CryoCor Receives FDA Approval for Right Atrial Flutter
4. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
9. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
10. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
11. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible figures ... of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):